Don't be too Quick to Jump on the Jardiance (empagliflozin) Bandwagon

You'll hear cautious optimism about cardiovascular benefits with the SGLT2 inhibitor, empagliflozin (Jardiance).

Until now, metformin seemed to be the only diabetes med linked to a reduction in cardiovascular events in patients with type 2 diabetes.

But new evidence suggests empagliflozin also reduces CV risk.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals